Evidence map›Paper›PMID 39137022›Full record

Observational studyJMIR research protocols2024

The Association Between Physical Distancing Behaviors to Avoid COVID-19 and Health-Related Quality of Life in Immunocompromised and Nonimmunocompromised Individuals: Patient-Informed Protocol for the Observational, Cross-Sectional EAGLE Study.

Paul Williams, Timothy A Herring, Renata T C Yokota, Tiago Maia, Sudhir Venkatesan, James C Marcus, Gabriella Settergren, Sofie Arnetorp, Andrew Lloyd, Johan L Severens and 7 more

Abstract readObservational Study
In one paragraph

Observational study in JMIR research protocols, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Paul Williams *Global Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0001-6259-0390
Timothy A Herring *Medical Evidence, Epidemiology, Vaccine & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, United States.ORCID 0000-0002-3475-8616
Renata T C YokotaP95, Epidemiology & Pharmacovigilance, Leuven, Belgium.ORCID 0009-0004-9752-5758
Tiago MaiaPatient Centered Solutions, IQVIA, Porto Salvo, Portugal.ORCID 0000-0001-5711-8155
Sudhir VenkatesanBPM Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom.ORCID 0000-0002-2093-5781
James C MarcusPatient Centered Solutions, IQVIA, Washington, DC, United States.ORCID 0000-0001-5223-4173
Gabriella SettergrenGlobal Evidence Portfolio Delivery, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.ORCID 0009-0002-2734-0454
Sofie ArnetorpHealth Economic & Payer Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.ORCID 0009-0004-7624-0091
Andrew LloydAcaster Lloyd Consulting Ltd, London, United Kingdom.ORCID 0000-0002-7597-6556
Johan L SeverensSeverens HTA Consultancy, Venray, Netherlands.ORCID 0000-0001-9590-0244
James W VarniTexas A&M University, College Station, TX, United States.ORCID 0000-0003-4816-4357
Sharon DixonPatient representative, Sulphur Springs, TX, United States.ORCID 0009-0003-2645-7498
Lweendo HamusankwaPatient representative, London, United Kingdom.ORCID 0009-0004-4354-8559
Philip A PowellSheffield Centre for Health and Related Research (SCHARR), University of Sheffield, Sheffield, United Kingdom.ORCID 0000-0003-1169-3431
Sylvia TaylorMedical Evidence, Vaccine & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom.ORCID 0000-0001-7803-0611
John E WareJohn Ware Research Group, Watertown, ME, United States.ORCID 0000-0002-0744-2149
Marieke KrolPatient Centered Solutions, IQVIA, Amsterdam, Netherlands.ORCID 0000-0002-6153-0828

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmunocompromised individuals are known to respond inadequately to SARS-CoV-2 vaccines, placing them at high risk of severe or fatal COVID-19. Thus, immunocompromised individuals and their caregivers may still practice varying degrees of social or physical distancing to avoid COVID-19. However, the association between physical distancing to avoid COVID-19 and quality of life has not been comprehensively evaluated in any study.

objectiveWe aim to measure physical distancing behaviors among immunocompromised individuals and the association between those behaviors and person-centric outcomes, including health-related quality of life (HRQoL) measures, health state utilities, anxiety and depression, and work and school productivity impairment.

methodsA patient-informed protocol was developed to conduct the EAGLE Study, a large cross-sectional, observational study, and this paper describes that protocol. EAGLE is designed to measure distancing behaviors and outcomes in immunocompromised individuals, including children (aged ≥6 mo) and their caregivers, and nonimmunocompromised adults in the United States and United Kingdom who report no receipt of passive immunization against COVID-19. We previously developed a novel self- and observer-reported instrument, the Physical Distancing Scale for COVID-19 Avoidance (PDS-C19), to measure physical distancing behavior levels cross-sectionally and retrospectively. Using an interim or a randomly selected subset of the study population, the PDS-C19 psychometric properties will be assessed, including structural validity, internal consistency, known-group validity, and convergent validity. Associations (correlations) will be assessed between the PDS-C19 and validated HRQoL-related measures and utilities. Structural equation modeling and regression will be used to assess these associations, adjusting for potential confounders. Participant recruitment and data collection took place from December 2022 to June 2023 using direct-to-patient channels, including panels, clinician referral, patient advocacy groups, and social media, with immunocompromising diagnosis confirmation collected and assessed for a randomly selected 25% of immunocompromised participants. The planned total sample size is 3718 participants and participant-caregiver pairs. Results will be reported by immunocompromised status, immunocompromising condition category, country, age group, and other subgroups.

resultsAll data analyses and reporting were planned to be completed by December 2023. Results are planned to be submitted for publication in peer-reviewed journals in 2024-2025.

conclusionsThis study will quantify immunocompromised individuals' physical distancing behaviors to avoid COVID-19 and their association with HRQoL as well as health state utilities. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR1-10.2196/52643.

Indexed as

COVID-19Immunocompromised HostPhysical DistancingQuality of LifeAdultChildCross-Sectional StudiesFemaleHumansMaleUnited KingdomUnited Statescost of illnessimmunosuppressionpatient participationpatient-reported outcome measuresprotocolquality of liferespiratory tract infectionSARS-CoV-2social isolationsurveys and questionnaires

Identifiers

PMID39137022
PMCPMC11350303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.